Astrana Health Sees FY24 EPS $1.12-$1.36 Vs $1.42 Est.; Revenue $1.75B-$1.85B Vs $1.76B Est.
Astrana Health Sees FY24 EPS $1.12-$1.36 Vs $1.42 Est.; Revenue $1.75B-$1.85B Vs $1.76B Est.
2024 Guidance:
2024年指引：
Taking all of Astrana's recent growth initiatives and capital allocation strategy into account, the Company is updating its revenue, net income attributable to Astrana, and EPS - diluted guidance for 2024 while reiterating guidance for Adjusted EBITDA for the year ending December 31, 2024.
考虑到Astrana的所有最近的增长举措和资本配置策略，该公司更新了其2024年营业收入、归属于Astrana的净利润和每股收益-摊薄指引，同时重申截至2024年12月31日的调整后EBITDA指引。额外信息请参见下面的“净利润与EBITDA和调整后EBITDA的指引对比”和“非GAAP财务指标的使用”。实际金额是否超出预期会产生重大影响，具体详情请参见下面的“前瞻性声明”。
| ($ in millions, except per share amounts) | 2024 Guidance Range | |||||||
| Low | High | |||||||
| Total revenue | $ | 1,750 | $ | 1,850 | ||||
| Net income attributable to Astrana Health, Inc. | $ | 54 | $ | 66 | ||||
| Adjusted EBITDA | $ | 165 | $ | 185 | ||||
| EPS – diluted | $ | 1.12 | $ | 1.36 | ||||
| （以百万美元计，除每股数据外） | 2024年指导范围 | |||||||
| 收盘最低价 | 高 | |||||||
| 总收入 | $ | 1,750 | $ | 1,850 | ||||
| Astrana Health，Inc.的净利润 | $ | 54 | $ | 66 | ||||
| 调整后的EBITDA | $ | 165 | $ | 185 | ||||
| 每股收益-摊薄 | $ | 1.12 | $ | 1.36 | ||||
See "Guidance Reconciliation of Net Income to EBITDA and Adjusted EBITDA" and "Use of Non-GAAP Financial Measures" below for additional information. There can be no assurance that actual amounts will not be materially higher or lower than these expectations. See "Forward-Looking Statements" below for additional information.
有关详细信息，请参阅以下“净利润与EBITDA和调整后EBITDA的指引对比”和“非GAAP财务指标的使用”。不能保证实际金额不会显著高于或低于这些预期。请参见下面的“前瞻性声明”获取更多信息。